My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

55.62 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
96 97 Next >
How Do Investors Really Feel About Novo Nordisk?
 
Via Benzinga
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
This dark horse candidate has emerged to take significant share in the weight-loss drugs space. 
Via Investor's Business Daily
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - A Strong Candidate for Value Investors
NOVO-NORDISK A/S (NYSE:NVO) is a strong value stock with high profitability, solid growth, and an attractive valuation, making it a candidate for long-term investors. 
Via Chartmill
Why Scholar Rock Shares Are Soaring Today
Via The Motley Fool
Topics Stocks
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 
Via Stocktwits
Topics Lawsuit
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial. 
Via Benzinga
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Why Novo Nordisk Stock Sank by Nearly 4% Today
Via The Motley Fool
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic. 
Via Benzinga
Topics Intellectual Property
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
1 Growth Stock Down 9% to Buy Right Now
Via The Motley Fool
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
Why Novo Nordisk Stock Pumped Higher on Thursday
Via The Motley Fool
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies. 
Via Stocktwits
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills
Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows. 
Via Benzinga
4 Dividend Stocks to Double Up on Right Now
The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners. 
Via The Motley Fool
Topics Artificial Intelligence
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Via The Motley Fool
Topics Artificial Intelligence Government
Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock?
Via The Motley Fool
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned. 
Via Benzinga
Nvidia Extends AI Reach In Europe With Alliances
Nvidia announced a flurry of alliances with European companies and governments that extend its influence in AI across the continent. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. 
Via Stocktwits
Topics Artificial Intelligence Economy
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity. 
Via Benzinga
Why Novo Nordisk Stock Just Popped
Novo Nordisk stock has multiple catalysts that could soon reverse is slide. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
2 Weight Loss Drug Stocks That Are Screaming Buys in June
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings. 
Via The Motley Fool
Why Novo Nordisk Stock Eked Out a Win on Monday
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
96 97 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.